Raj Prabhakar work email
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
Raj Prabhakar personal email
- Valid
Raj Prabhakar phone numbers
Experienced C-Level executive leader in gene, cell, viral vector and vaccines with 20 years global industry experience, recently in pediatric rare diseases and oncology- Public company senior executive experience in biotechnology with ex-vivo (autologous cell and gene) and in-vivo (AAV gene DNA and RNA therapy) development, with domain experience in pediatric rare disease, cardiology, oncology, oligonucleotides, immunotherapy, HSC stem cells and vaccines. Global experience in US, EMA, as well as Emerging Markets including China & Asia-Pacific.- Led banking syndicate diligence on behalf of Executive Leadership team that has raised over $1.1 Billion in institutional capital gross proceeds over last 6 years from leading Wall St. investment banks (Morgan Stanley, JP Morgan, Evercore, SVB Leerink, TD Cowen, BAML) - transactions ranging from $75 million to $300 million from leading healthcare hedge and mutual fund investors.- Manage external LRP, valuation, and banking, advisory relationships.- Operating experience in supply chain and manufacturing within GMP cell processing, viral vector, plasmid production and tangential areas within cell and gene therapy. Source, lead and negotiate manufacturing and supply agreements for drug substance, drug product, bioreactor and equipment, and facilities. - Experienced in in-and-out-licensing (IP) partnerships, fundraising and IR, advisory, private equity, venture capital, M&A.- Led all deal structuring through execution of multi-capsid AAV gene therapy license with REGENXBIO;- Secured License and development collaborations for China and Japan Territories, 2 largest markets for HCC liver cancer indication (negotiated all terms including milestones, royalties and development obligations);- Led all deal structuring through execution of $105 million M&A of PCT to Hitachi Chemical (Japan) for state of the art global cell processing facilities in complex 2-stage transactions;- Led all deal structuring through execution of complex License, JV and long term Supply agreement with Zhejiang Hisun for the Greater China Territory;- Led planning activities for US product launch, product marketing and pricing, patent protection & life cycle management;Specialties: biopharma product development from preclinical to P III. Managing timelines, budgets, licensing and partnerships, CMC, clinical development, and ongoing technology validation. Particular focus on joint Eastern-Western development projects - projects in Asia Pacific to utilize global clinical and development and manufacturing opportunities.
-
Venture PartnerRtw Investments, LpNew York, Ny, Us
-
Chief Business Officer & Senior Vice PresidentRocket Pharmaceuticals Oct 2017 - PresentCranbury, New Jersey, UsServe on ELT - Executive Leadership TeamEmployee #8 (Pre-IPO)• Lead all corporate and business development transactions, licensing (in-and-out), partnerships, program and project management, procurement and business operations for clinical , manufacturing-CMC and pre-commercial planning;• Manage BD activity from due diligence, contract and term sheet negotiation, valuation, to final license transaction execution. Work in matrix environment and triage between Clinical, CMC, Regulatory and Finance; Manage portfolio of patent and data licenses, IP schedules and obligations;• FP&A: Commercial forecasting and market for 6 (3 CD34 LVV Heme and 3 AAV Cardiovascular) engineered rare disease gene therapy programs: Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD)), and AAV for Danon Disease, PKP2 Heart Failure, and BAG3 Dilated Cardiomyopathy; Constructed and manage company-wide 15 year LRP (Long Range Plan) for pipeline; • Have served at GPH (Global Program Head) of multiple AAV programs including PKP2 and BAG3 AAV cardiovascular development programs, overseeing all aspects of development from initial IP filing, vector development and manufacturing, technology transfer through IND enabling studies and clinical enrollment of Phase I. • Involvement with broader corporate strategy, partnerships, and M&A opportunities alongside legal team; Primary company lead for all in-licensing and new pipeline opportunity evaluation (platforms and clinical indications) with emphasis on heart failure and new therapeutic indications;• Prior to hiring of VP Manufacturing, served as interim head of manufacturing for construction, budget, timeline, equipment procurement and RFPs, hiring and governance for 103,000 sq. ft. state-of-the-art viral vector gene therapy clinical and commercial facility. -
Senior Vice President Business DevelopmentCaladrius Biosciences Aug 2015 - Oct 2017Basking Ridge, Nj, UsReported directly to CEO and served on Executive Committee. Responsible for leading all corporate business development activities, including in-and-out-licensing, as well as M&A and divestitures of autologous ex-vivo cell therapy products.Current portfolio candidates include:- T-Reg Immune Modulation cell therapy program - Randomized Phase II trial addressing Type I diabetes and autoimmune diseases with polyclonal regulatory T-cells; follow-on indications include Lupus, GVHD, and NMO;- Immune-Oncology cell therapy program based on activated dendiritic cells - Phase III trial in Melanoma under SPA and entering Phase I/II for Ovarian Ca and HCC liver cancer;- Cardiac ischemic repair cell therapy program based on CD34+ cells - addressing CLI critical limb ischemia, in addition to CHF congestive heart failure;Assist manufacturing subsidiary PCT LLC in strategic collaborations including Hitachi Chemical Ltd. (Asia Pacific and Japan collaboration). PCT's current customer focus includes leading customers in CAR-T, gene editing, and autologous ex-vivo approaches for cell and gene therapy primarily in orphan diseases -
Vice President Business DevelopmentCelsion Corporation (Egen, Inc) Jan 2004 - Jul 2015Us2014-2015 - Appointed Head of Business Development for Celsion - EGEN2009-2014 - Executive Director, Business Development.2007-2009 - Sr. Director, Clinical Program Management for Liver Cancer Programs.2004-2007 - Director, Sr. Director, Strategic Planning, Business Development.Celsion-EGEN is focused on commercializing in-vivo drug-development technologies for various cancer and non-cancer clinical indications.Lead all merger-integration activities in multiple locations after acquisition of EGEN, Inc, focused on gene and immunotherapy with DNA and RNA drug candidates. Report directly to CEO, and work primary with clinical development and operations teams in matrix environment.Prior to merger, held both corporate and operating roles to develop and commercialize primary liver cancer indication (Hepatocellular Carcinoma), company's lead drug candidate. Role involves all aspects of project management and business development, focused on accelerating lead drug candidate from to commercialization. Significant ex-US on-the-ground experience to set up global clinical trials in 11 countries, source manufacturing (CMC), and partner for Phase III registration trial. Particular experience in Asia (and China). Current portfolio candidates include:- ThermoDox, in pivotal Ph III for HCC liver cancer and Ph II for breast cancer;- TheraPlas IL-12 DNA-based immunotherapy, entering Ph II for ovarian cancer and Phase I for GBM brain cancer;- TheraPlas BD-15 for mRNA, DNA Plasmid and in-vivo CRISPR-Cas9 delivery for lung therapeutics;- TheraSilence for siRNA and microRNA delivery and gene silencing;- RAST - RNA Amplification and Secretion Technology, biological production of RNA;- Crossamine DNA plasmid and Staramine RNA Transfection reagent business;Lead all in-licensing and out-licensing activities for pro-forma company, and manage partnership dashboard, with contacts at nearly 100 global biopharma companies.Manage IP portfolio and dockets, and FTO opinions. -
Senior Commercialization Officer, VaccinesPath Global Vaccine Development Program Feb 2014 - Jul 2014Seattle, Wa, UsPATH is an international NGO developing technology and vaccine solutions for the developing world, with a global staff over 1,300 and annual budget nearly $350 million, largely supported by the Bill and Melinda Gates Foundation, Wellcome Trust, DFID and USAID.Served as a member of the VAC Commercialization and Corporate Partnership team in a leadership role for licensing and partnerships with public, private (pharma and biotech), academic and government organizations.Direct licensing and partnership responsibilities included investigational vaccine programs targeting clinical indications for ETEC, Shigella and Rotavirus, primarily targeting Emerging markets (Africa, South Asia, Latin America).Evaluated addressable markets for both endemic (pediatric, developing world) and travelers / military markets (adult, western population) in bifurcated approach to partnering with global pharmaceutical companies. -
Director Of Corporate DevelopmentProtiveris Jul 2002 - Dec 2003Early-stage diagnostic and device company in bionanotechnology. Next generation diagnostic tools for gene and protein markets (i.e. cancer markers) for label-free detection at nano detection levels.Reported directly to COO of company.
-
Assistant To Ceo, Director Of Corporate DevelopmentOsiris Therapeutics 2002 - 2002UsLeading biotechnology company in allogeneic stem cell therapy (adult human mesenchymal stem cells).Reported directly to CEO and presented to Board of Directors to develop business and product development plans for stem cell therapies for 7 product lines. -
StudentHarvard Business School Sep 1999 - Jun 2001Boston, Ma, UsFull-time graduate student in MBA program. -
AssociateVertex Venture Management Pte Ltd 2001 - 2001Venture Capital associate.
-
Associate, Private EquitySwander Pace Capital 1997 - 1999San Francisco, Ca, Us
Raj Prabhakar Skills
Raj Prabhakar Education Details
-
Harvard Business SchoolMba -
Massachusetts Institute Of TechnologyMechanical Engineering (Course Ii)
Frequently Asked Questions about Raj Prabhakar
What company does Raj Prabhakar work for?
Raj Prabhakar works for Rtw Investments, Lp
What is Raj Prabhakar's role at the current company?
Raj Prabhakar's current role is Venture Partner.
What is Raj Prabhakar's email address?
Raj Prabhakar's email address is rp****@****ius.com
What is Raj Prabhakar's direct phone number?
Raj Prabhakar's direct phone number is +160989*****
What schools did Raj Prabhakar attend?
Raj Prabhakar attended Harvard Business School, Massachusetts Institute Of Technology.
What skills is Raj Prabhakar known for?
Raj Prabhakar has skills like Biotechnology, Biopharmaceuticals, Clinical Development, Oncology, Pharmaceutical Industry, Commercialization, Private Equity, Mergers And Acquisitions, Venture Capital, Clinical Research, Licensing, Drug Development.
Who are Raj Prabhakar's colleagues?
Raj Prabhakar's colleagues are Arlene Lauron, Teysha Popescu, David Moore, Matt Lane, Cpa, Tony Nguyen, Sweeny Pillot, Mirabelle Mi.
Free Chrome Extension
Find emails, phones & company data instantly
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial